Skip to main content

Table 2 Serum testosterone on each days after switching to lueprolide

From: Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist

  

Day 0

Day 1

Day 2

Day 5

Day 7

ECLIA

Total (n = 39)

7.5 ± 5.8

19.7 ± 27.5

17.4 ± 18.2

7.0 ± 4.8

6.7 ± 4.6

 

Surge (-)

     
 

Total (n = 36)

7.6 ± 6.0

13.5 ± 10.6

14.3 ± 11.2

7.1 ± 4.8

6.8 ± 4.7

 

3 m group (n = 9)

8.2 ± 6.8

11.9 ± 10.6

11.9 ± 11.4

7.9 ± 5.7

6.9 ± 5.0

 

2 m group (n = 9)

6.0 ± 5.6

10.6 ± 11.9

9.0 ± 8.0

6.0 ± 5.7

6.3 ± 5.6

 

1 m group (n = 19)

8.2 ± 5.9

15.7 ± 5.9

18.2 ± 11.5

7.2 ± 4.0

7.1 ± 4.1

 

Surge (+)

     
 

No.10 (3 m)

10.0

161.0

88.0

3.0

3.0

 

No.18 (2 m)

3.0

63.0

69.0

3.0

3.0

 

No.30 (1 m)

3.0

59.0

5.0

12.0

9.0

LC-MS/MS

Total (n = 36)

8.6 ± 4.4

24.1 ± 25.3

22.6 ± 20.6

8.6 ± 2.7

8.0 ± 3.0

 

Surge (-)

     
 

Total (n = 33)

7.9 ± 3.0

17.9 ± 10.3

19.1 ± 13.4

8.4 ± 2.6

7.6 ± 2.6

 

3 m group (n = 9)

8.6 ± 3.3

15.7 ± 12.3

15.4 ± 11.5

8.4 ± 3.4

8.0 ± 3.1

 

2 m group (n = 8)

6.4 ± 2.6

14.9 ± 12.5

11.1 ± 11.1

6.8 ± 2.7

6.6 ± 3.2

 

1 m group (n = 16)

8.3 ± 2.9

20.8 ± 7.4

24.4 ± 13.7

9.2 ± 1.6

7.9 ± 1.9

 

Surge (+)

     
 

No.10 (3 m)

28.0

142.0

93.0

12.0

16.0

 

No.18 (2 m)

12.0

72.0

80.0

9.0

12.0

 

No.30 (1 m)

7.0

63.0

7.0

12.0

9.0

  1. Data are presented as means ± SD unless indicated otherwise
  2. ECLIA electrochemiluminescence Immunoassay; LC-MS/MS liquid chromatography-tandem mass spectrometry; surge (-) means a testosterone surge of down to 50 ng/dl was observed, surge (+) means a testosterone surge of up to 50 ng/dl was observed